Treatment of duchenne muscular dystrophy
US8138351B2 · kind B2 · utility
1Cited by
1References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 14, 2008 |
| Grant date | Mar 20, 2012 |
| Priority date | — |
| Expiry date | Jan 12, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P21/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a process for the preparation of 5-(ethylsulfonyl)-2-(naphthalen-2-yl) benzo[d] oxazole useful in the treatment of Duchenne muscular dystrophy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.